Tango Biosciences

Michael Scholle Appointed CEO of Tango Biosciences

Co-founder Brian Kay to assume Chief Scientific Officer, focused on scientific innovation and operations Press Release – January 07, 2025 – CHICAGO – Tango Biosciences, Inc., the premier research partner for custom affinity reagents by phage display, announced Michael Scholle, MS, MBA as Chief Executive Officer effective immediately. Scholle is one of three co-founders of Tango Biosciences and an active board member. This transition enables president and … Continue reading Michael Scholle Appointed CEO of Tango Biosciences

City Therapeutics, Inc.

City Therapeutics Appoints Andy Orth as Chief Executive Officer

Orth brings more than 25 years of global industry experience to CEO role, with strong track record in corporate and commercial strategy City co-founder Dr. John Maraganore to retain active executive chair role to ensure company leads next-generation RNAi therapeutics CAMBRIDGE, Mass – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the appointment of Andrew “Andy” Orth … Continue reading City Therapeutics Appoints Andy Orth as Chief Executive Officer

Maurice van Tilburg

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization Los Angeles and Amsterdam – December 30, 2024 – Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA RenovaroCube. … Continue reading Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Cure Rare Disease

Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

Press Release – December 18, 2024 – WOODBRIDGE, Conn. – Cure Rare Disease, a nonprofit biotechnology organization dedicated to advancing treatments for neglected rare and genetic diseases, is proud to announce Brittany Stineman as its new Chief Advancement Officer, effective January 2025. “Brittany’s story is a testament to the power of hope, resilience, and action” Post this As a mother who faced the unimaginable journey … Continue reading Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

Adicet Bio

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Press Release – December 18, 2024 – REDWOOD CITY, Calif. & BOSTON – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie … Continue reading Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer